Home > Insider Trading > Filing (0001599901-25-000039)

Filing Details

Accession Number:: 0001599901-25-000039
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-01-23 20:14:00
Reporting Period:: 2025-01-21

Accepted Time:: 2025-01-23 20:14:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1599901	Avidity Biosciences Inc.	RNA	Pharmaceutical Preparations (2834)	461336960

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1862121	Teresa Mccarthy	C/O Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego CA 92121	Chief Human Resources Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-01-21	1,738	$28.59	106,129	No	4	S	Direct
Common Stock	Disposition	2025-01-21	1,221	$28.60	104,908	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.
This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.08. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.63. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.